Lightlake Therapeutics, which is developing naloxone nasal sprays for several eating disorders, has announced the appointment of former FDA Commissioner David Kessler as a strategic advisor. Kessler is the author of The End of Overeating: Taking Control of the Insatiable American Appetite.
Lightlake CEO Roger Crystal commented, “We are very pleased to add Dr. Kessler as a strategic advisor. With his wide range of experience in research, clinical medicine, education, administration, and law, Dr. Kessler will be a tremendous guide for us as we work to develop a range of treatments to common addictive disorders. Specifically, Dr. Kessler’s major involvement with us will be to advise on the side-effects of addiction.”
The company recently reported positive Phase 2 results for its naloxone nasal spray for the treatment of binge eating disorder. A Phase 2 study of naloxone nasal spray for the treatment of bulimia nervosa is scheduled for 2013.
Read the Lightlake press release.
